Leads Biolabs' Opamtistomig Shows Robust Response And PFS Benefits In First-Line NSCLC

Leads Biolabs announced updated Phase II data for opamtistomig (LBL-024), its proprietary PD-L1/4-1BB bispecific antibody, combined with chemotherapy as a first-line treatment for non-small cell lung cancer. The data were presented in an oral session at the 2026 World Conference; the provided article text does not disclose efficacy, safety, or financial results.